2026
A Novel Anti-EphrinB2 Neutralizing Antibody Suppresses Fibrosis and Modulates Systemic Sclerosis Gene Signatures in Preclinical Models
Presented at the 2026 Fibrosis: Cross Organ Pathology and Pathways to Clinical Development, Banff, Alberta, Canada

2026
Accelerated Drug Discovery for First-in-Class Fibrosis Therapy
Download the case study to learn how Mediar Therapeutics and Alloy Therapeutics advanced antibody programs from concept to clinic ahead of schedule.

2025
Jeffrey Bornstein et al
A Phase 1 trial to evaluate the safety, PK and target engagement of MTX-463, a monoclonal antibody inhibitor of WISP1
Presented at the 2025 ERS Congress, Amsterdam, Netherlands

2025
Benjamin Wilks et al
Gene Signature in Systemic Sclerosis Modulated by a Human IgG1 Monoclonal Antibody that Neutralizes EphrinB2
Presented at the 19th International Workshop on Scleroderma Research, Cambridge, UK

2024
Paul Yaworsky et al
Anti-WISP1 (MTX-463) as a Novel Potential Therapy for Idiopathic Pulmonary Fibrosis
Presented at the Keystone Symposia on Fibrosis: Inflammation, Drivers and Therapeutic Resolution, Whistler, BC, Canada

2024
Gabriela Dower, et al
Anti-WISP1 (MTX-463) as a Novel Potential Therapy for Idiopathic Pulmonary Fibrosis
Presented at The American Thoracic Society International Conference

2024
Benjamin T. Wilks, et al
Anti-EphrinB2 neutralizing antibody suppresses fibrosis in preclinical in vitro and in vivo models
Presented at The 4th Congress on the EPH/Ephrins System

2023
BM Kim et al
WISP1 Neutralization Suppresses Fibrosis in Preclinical in vivo and ex vivo Models
Presented at the Keystone Symposia on Fibrosis Pathogenesis and Resolution: From Mechanism to Therapies

2022
P Yaworsky et al
miR-15a Reprograms Activated Hepatic Stellate Cells Back Towards Quiescence by Targeting WISP1.
Presented at the 3^rd International Conference on Tissue Repair, Regeneration, and Fibrosis